(VIANEWS) – Corcept Therapeutics Incorporated (CORT), Ellington Financial LLC (EFC), Alphabet (GOOG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Corcept Therapeutics Incorporated (CORT)
35.4% sales growth and 21.91% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $1.05.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 28.73. Meaning, the purchaser of the share is investing $28.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.91%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 8% and a negative 14.3%, respectively.
Volume
Today’s last reported volume for Corcept Therapeutics Incorporated is 1374270 which is 29.26% above its average volume of 1063150.
Sales Growth
Corcept Therapeutics Incorporated’s sales growth is 41.5% for the ongoing quarter and 35.4% for the next.
Yearly Top and Bottom Value
Corcept Therapeutics Incorporated’s stock is valued at $30.17 at 16:22 EST, way under its 52-week high of $34.28 and way higher than its 52-week low of $20.84.
2. Ellington Financial LLC (EFC)
34.3% sales growth and 5.27% return on equity
Ellington Financial Inc., through its subsidiary, Ellington Financial Operating Partnership LLC, acquires and manages mortgage-related, consumer-related, corporate-related, and other financial assets in the United States. The company acquires and manages residential mortgage-backed securities (RMBS) backed by prime jumbo, Alt-A, manufactured housing, and subprime residential mortgage loans; RMBS for which the principal and interest payments are guaranteed by the U.S. government agency or the U.S. government-sponsored entity; residential mortgage loans; commercial mortgage-backed securities; commercial mortgage loans and other commercial real estate debt; and residential mortgage loans. It also provides collateralized loan obligations; mortgage-related and non-mortgage-related derivatives; equity investments in mortgage originators; and other strategic investments. In addition, the company offers consumer loans and asset-backed securities backed by consumer and commercial assets. Ellington Financial LLC was founded in 2007 and is based in Old Greenwich, Connecticut.
Earnings Per Share
As for profitability, Ellington Financial LLC has a trailing twelve months EPS of $0.63.
PE Ratio
Ellington Financial LLC has a trailing twelve months price to earnings ratio of 19.06. Meaning, the purchaser of the share is investing $19.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.27%.
Yearly Top and Bottom Value
Ellington Financial LLC’s stock is valued at $12.01 at 16:22 EST, way below its 52-week high of $14.21 and way above its 52-week low of $10.88.
Sales Growth
Ellington Financial LLC’s sales growth for the next quarter is 34.3%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 6.1%, now sitting on 246.99M for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 31, 2024, the estimated forward annual dividend rate is 1.56 and the estimated forward annual dividend yield is 12.99%.
3. Alphabet (GOOG)
22.5% sales growth and 29.76% return on equity
Alphabet Inc. provides various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment offers products and services, including ads, Android, Chrome, hardware, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play store; and Fitbit wearable devices, Google Nest home products, Pixel phones, and other devices, as well as in the provision of YouTube non-advertising services. The Google Cloud segment offers infrastructure, platform, and other services; Google Workspace that include cloud-based collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells health technology and internet services. The company was founded in 1998 and is headquartered in Mountain View, California.
Earnings Per Share
As for profitability, Alphabet has a trailing twelve months EPS of $6.52.
PE Ratio
Alphabet has a trailing twelve months price to earnings ratio of 26.75. Meaning, the purchaser of the share is investing $26.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.76%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.4%, now sitting on 318.15B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 27.1% and 29.8%, respectively.
Moving Average
Alphabet’s value is above its 50-day moving average of $164.37 and way above its 200-day moving average of $144.75.
Yearly Top and Bottom Value
Alphabet’s stock is valued at $174.42 at 16:22 EST, under its 52-week high of $179.95 and way above its 52-week low of $115.83.
Previous days news about Alphabet(GOOG)
- According to Zacks on Thursday, 6 June, "Another better-ranked stock from the broader technology sector is Alphabet (GOOGL Quick QuoteGOOGL – Free Report) , sporting a Zacks Rank #1 (Strong Buy) at present. "
- According to Zacks on Wednesday, 5 June, "Apple has been playing catch-up in the AI space compared with Alphabet (GOOGL Quick QuoteGOOGL – Free Report) , Microsoft (MSFT Quick QuoteMSFT – Free Report) and Amazon (AMZN Quick QuoteAMZN – Free Report) , its peers in the "magnificent seven" group.", "Per sources, including Bloomberg, it has been actively involved in discussions with Alphabet to license Google’s Large Language Model (LLM), Gemini, for the iPhone. "
- Alphabet taps eli lilly's anat ashkenazi as new CFO. According to CNBC on Wednesday, 5 June, "Eli Lilly Chief Financial Officer Anat Ashkenazi will become Alphabet’s new CFO effective July 31, Google’s parent company announced Tuesday, almost a year after Alphabet first announced that current CFO Ruth Porat would move into a new role as president and chief investment officer.", "We’re very pleased to have found such a strong CFO, with a track record of strategic focus on long-term investment to fuel innovation and growth," Alphabet CEO Sundar Pichai said in a release."
- According to Zacks on Thursday, 6 June, "Companies like Microsoft, Meta Platforms and Alphabet are rapidly expanding their AI computing capabilities, boosting NVIDIA’s growth. "
- According to Zacks on Wednesday, 5 June, "Some other top-ranked stocks from the broader technology sector are AppFolio (APPF Quick QuoteAPPF – Free Report) , Arista Networks (ANET Quick QuoteANET – Free Report) and Alphabet (GOOGL Quick QuoteGOOGL – Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. "
4. Simulations Plus (SLP)
10.7% sales growth and 6.16% return on equity
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
Earnings Per Share
As for profitability, Simulations Plus has a trailing twelve months EPS of $0.52.
PE Ratio
Simulations Plus has a trailing twelve months price to earnings ratio of 90.48. Meaning, the purchaser of the share is investing $90.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Volume
Today’s last reported volume for Simulations Plus is 55617 which is 44.97% below its average volume of 101076.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 5% and positive 750% for the next.
Sales Growth
Simulations Plus’s sales growth for the next quarter is 10.7%.
5. KKR & Co. (KKR)
9.9% sales growth and 10.86% return on equity
KKR & Co. Inc. is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, management buyouts, credit special situations, growth equity, mature, mezzanine, distressed, turnaround, lower middle market and middle market investments. The firm considers investments in all industries with a focus on software, security, semiconductors, consumer electronics, internet of things (iot), internet, information services, information technology infrastructure, financial technology, network and cyber security architecture, engineering and operations, content, technology and hardware, energy and infrastructure, real estate, services industry with a focus on business services, intelligence, industry-leading franchises and companies in natural resource, containers and packaging, agriculture, airports, ports, forestry, electric utilities, textiles, apparel and luxury goods, household durables, digital media, insurance, brokerage houses, non-durable goods distribution, supermarket retailing, grocery stores, food, beverage, and tobacco, hospitals, entertainment venues and production companies, publishing, printing services, capital goods, financial services, specialized finance, pipelines, and renewable energy. In energy and infrastructure, it focuses on the upstream oil and gas and equipment, minerals and royalties and services verticals. In real estate, the firm seeks to invest in private and public real estate securities including property-level equity, debt and special situations transactions and businesses with significant real estate holdings, and oil and natural gas properties. The firm also invests in asset services sector that encompasses a broad array of B2B, B2C and B2G services verticals including asset-based, transport, logistics, leisure/hospitality, resource and utility support, infra-like, mission-critical, and environmental services. Within Americas, the firm prefers to invest in consumer products; chemicals, metals and mining; energy and natural resources; financial services; healthcare; industrials; media and communications; retail; and technology. Within Europe, the firm invests in consumer and retail; energy; financial services; health care; industrials and chemicals; media and digital; and telecom and technologies. Within Asia, it invests in consumer products; energy and resources; financial services; healthcare; industrials; logistics; media and telecom; retail; real estate; and technology. It also seeks to make impact investments focused on identifying and investing behind businesses with positive social or environmental impact. The firm seeks to invest in mid to high-end residential developments, but can invest in other projects throughout Mainland China through outright ownership, joint ventures, and merger. It invests globally with a focus on Australia, emerging and developed Asia, Middle East and Africa, Nordic, Southeast Asia, Asia Pacific, Ireland, Hong Kong, Japan, Taiwan, India, Vietnam, Malaysia, Singapore, Indonesia, France, Germany, Netherlands, United Kingdom, Caribbean, Mexico, South America, North America, Brazil, Latin America, Korea with a focus on South Korea, and United States of America. In the United States and Europe, the firm focuses on buyouts of large, publicly traded companies. It seeks to invest $30 million to $717 million in companies with enterprise values between $500 million to $2389 million. The firm prefers to invest in a range of debt and public equity investing and may co-invest. It seeks a board seat in its portfolio companies and a controlling ownership of a company or a strategic minority positions. The firm may acquire majority and minority equity interests, particularly when making private equity investments in Asia or sponsoring investments as part of a large investor consortium. The firm typically holds its investment for a period of five to seven years and more and exits through initial public offerings, secondary offerings, and sales to strategic buyers. KKR & Co. Inc. was founded in 1976 and is based in New York, New York with additional offices across North America, Europe, Australia, Sweden and Asia.
Earnings Per Share
As for profitability, KKR & Co. has a trailing twelve months EPS of $4.09.
PE Ratio
KKR & Co. has a trailing twelve months price to earnings ratio of 23.79. Meaning, the purchaser of the share is investing $23.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.86%.
Yearly Top and Bottom Value
KKR & Co.’s stock is valued at $97.29 at 16:22 EST, under its 52-week high of $108.00 and way higher than its 52-week low of $52.95.
Sales Growth
KKR & Co.’s sales growth is 5.5% for the current quarter and 9.9% for the next.
Previous days news about KKR & Co.(KKR)
- According to Zacks on Wednesday, 5 June, "Similarly, KKR & Co. Inc. (KKR Quick QuoteKKR – Free Report) entered into a strategic partnership with Capital Group to augment alternative investment solutions for client portfolios. "
6. Interactive Brokers Group (IBKR)
6.6% sales growth and 21.62% return on equity
Interactive Brokers Group, Inc. operates as an automated electronic broker worldwide. The company engages in the execution, clearance, and settlement of trades in stocks, options, futures, foreign exchange instruments, bonds, mutual funds, exchange traded funds (ETFs), precious metals, and cryptocurrencies. It also custodies and services accounts for hedge and mutual funds, ETFs, registered investment advisors, proprietary trading groups, introducing brokers, and individual investors. In addition, the company offers custody, prime brokerage, securities, and margin lending services. It serves institutional and individual customers through electronic exchanges and market centers. The company was founded in 1977 and is headquartered in Greenwich, Connecticut.
Earnings Per Share
As for profitability, Interactive Brokers Group has a trailing twelve months EPS of $2.84.
PE Ratio
Interactive Brokers Group has a trailing twelve months price to earnings ratio of 38.91. Meaning, the purchaser of the share is investing $38.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.62%.
7. Novartis AG (NVS)
5.9% sales growth and 19.83% return on equity
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Earnings Per Share
As for profitability, Novartis AG has a trailing twelve months EPS of $4.1.
PE Ratio
Novartis AG has a trailing twelve months price to earnings ratio of 22.81. Meaning, the purchaser of the share is investing $22.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.83%.
8. Covenant Logistics Group (CVLG)
5.6% sales growth and 10.78% return on equity
Covenant Logistics Group, Inc., together with its subsidiaries, provides transportation and logistics services in the United States. It operates through four segments: Expedited, Dedicated, Managed Freight, and Warehousing. The Expedited segment primarily provides truckload services with high service freight and delivery standards, such as 1,000 miles in 22 hours or 15-minute delivery windows. The Dedicated segment provides customers with committed truckload capacity over contracted periods using equipment either owned or leased by the company. The Managed Freight segment offers brokerage services, including logistics capacity by outsourcing the carriage of customers' freight to third parties; and transport management services, such as logistics services on a contractual basis to customers who prefer to outsource their logistics needs. The Warehousing segment provides day-to-day warehouse management services to customers. This segment also provides shuttle and switching services to shuttling containers and trailers. The company also engages in used equipment sales and leasing business. It serves transportation companies, such as parcel freight forwarders, less-than-truckload carriers, and third-party logistics providers; and traditional truckload customers, including manufacturers, retailers, and food and beverage shippers. The company was formerly known as Covenant Transportation Group, Inc. and changed its name to Covenant Logistics Group, Inc. in July 2020. Covenant Logistics Group, Inc. was founded in 1986 and is based in Chattanooga, Tennessee.
Earnings Per Share
As for profitability, Covenant Logistics Group has a trailing twelve months EPS of $3.04.
PE Ratio
Covenant Logistics Group has a trailing twelve months price to earnings ratio of 15.23. Meaning, the purchaser of the share is investing $15.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.78%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 7, 2024, the estimated forward annual dividend rate is 0.44 and the estimated forward annual dividend yield is 0.95%.
Yearly Top and Bottom Value
Covenant Logistics Group’s stock is valued at $46.31 at 16:22 EST, way below its 52-week high of $57.57 and way higher than its 52-week low of $38.06.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 8.4% and positive 3.5% for the next.
